If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
11 June 2020 A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
18 May 2021 A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
11 June 2020 A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
18 May 2021 A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
11 June 2020 A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
27 August 2020 Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
18 May 2021 A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
